Biodistribution and metabolism of [N-methyl-11C]-m-hydroxyephedrine in the rat

Nuclear Medicine and Biology

Volumn 24, Issue 5, 1997, Pages 417-424

  Law, Marilyn P ^a   Osman, Safiye ^a   Davenport, Raymond J ^a   Cunningham, Vincent J ^a   Pike, Victor W ^a   Camici, Paolo G ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Heart; Hydroxyephedrine; Metaraminol; Noradrenaline re uptake; PET; Rat

Indexed keywords

DESIPRAMINE; EPHEDRINE DERIVATIVE; HYDROXYEPHEDRINE N METHYL C 11; METARAMINOL; UNCLASSIFIED DRUG;

ARTICLE; DOSE RESPONSE; DRUG DISTRIBUTION; DRUG METABOLISM; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; POSITRON EMISSION TOMOGRAPHY; RAT;

EID: 0030876088     PISSN: 09698051     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0969-8051(97)00007-3     Document Type: Article

References (27)

1. Allman K. C., Stevens M. J., Wieland D. M., Hutchins G. D., Wolfe E. R. Jr., Greene D. A. and Schwaiger M. (1993) Noninvasive assessment of cardiac diabetic neuropathy by carbon-11 hydroxyephedrine and positron emission tomography. J. Am. Coll. Cardiol. 22, 1425-432.
2. Allman K. C., Wieland D. M., Muzik O., Degrado T. R., Wolfe E. R. Jr. and Schwaiger M. (1993) Carbon-11 hydroxyephedrine with positron emission tomography for serial assessment of cardiac adrenergic neuronal function after acute myocardial infarction in humans. J. Am. Coll. Cardiol. 22, 368-375.
3. Barker E. L. and Blakely R. D. (1995) Norepinephrine and serotonin transporters. In: Psychopharmacology: The Fourth Generation of Progress. (Edited by Bloom F. E. and Kupfer D. J.), pp. 321-333. Raven Press, New York.
4. Brush J. E., Eisenhofer G., Garty M., Stall R., Maron B. J., Cannon III R. O., Panza J. A., Epstein S. E. and Goldstein D. S. (1989) Cardiac norepinephrine kinetics in hypertrophic cardiomyopathy. Circulation 79, 836-844.
5. Calkins H., Allman K., Bolling S., Kirsch M., Wieland D., Morady F. and Schwaiger M. (1993) Correlation between scintigraphic evidence of regional sympathetic neuronal dysfunction and ventricular refractoriness in the human heart. Circulation 88, 172-179.
6. Crout J. R., Alpers H. S., Tatum E. L. and Shore P. A. (1964) Release of metaraminol (aramine) from the heart by sympathetic nerve stimulation. Science 145, 828-829.
7. 3H]desipramine binding sites in the rat brain after acute and chronic treatment with imipramine. J. Pharm. Pharmacol. 43, 31-35.
8. de Grado T. R., Hutchins G. D., Toorongian S. A., Wieland D. M. and Schwaiger M. (1993) Myocardial kinetics of carbon-11-meta-hydroxyephedrine: Retention mechanisms and effects of norepinephrine. J. Nucl. Med. 34, 1287-1293.
9. Fuller R. W., Snoddy H. D., Perry K. W., Bernstein J. R. and Murphy P. J. (1981) Formation of α-methylnorepinephrine as a metabolite of metaraminol in guinea pigs. Biochem. Pharmacol. 30, 2831-2836.
10. Kawai C., Yui Y., Hoshino T., Sasayama S. and Matsumori A. (1983) Myocardial catecholamines in hypertrophic and dilated (congestive) cardiomyopathy: A biopsy study. J. Am. Coll. Cardiol. 2, 834-840.
11. Kopin I. J. (1968) False adrenergic transmitters. Annu. Rev. Pharmacol. 8, 377-394.
12. 3H]DMI binding is associated with neuronal noradrenaline uptake in the periphery and the central nervous system. Eur. J. Pharmacol. 72, 423-424.
13. Law M. P. (1993) Demonstration of the suitability of CGP 12177 for in vivo studies of β-adrenoceptors. Br. J. Pharmacol. 109, 1101-1109.
14. Lefroy D. C., de Silva R., Choudhury L., Uren N. G., Crake T., Rhodes C. G., Lammertsma A. A., Boyd H., Patsalos P. N., Nihoyannopoulos P., Oakley C. M., Jones T. and Camici P. G. (1993) Diffuse reduction of myocardial beta-adrenoceptors in hypertrophic cardiomyopathy: A study with positron emission tomography. J. Am. Coll. Cardiol. 22, 1653-1660.
15. 11C]MHED. J. Nucl. Med. 37, 205P.
16. 18F]Fluorometaraminol: A radiotracer for in vivo mapping of adrenergic nerves of the heart. J. Med. Chem. 31, 362-366.
17. Nelder J. A. and Mead R. (1965) A simple algorithm for function minimization. Comput. J. 7, 308-313.
18. 11C]meta-Hydroxyephedrine -determination of labelled metabolites in rat plasma and heart and in serial plasma samples from human subjects during PET studies. J. Label. Compd. Radiopharm. 37, 712-714.
19. 3H]Desipramine labels with high affinity the neuronal transporter for adrenaline in the frog heart. Eur. J. Pharmacol. 127, 277-280.
20. 3H]DMI binding in the periphery and the central nervous system: A specific site associated with the neuronal uptake of noradrenaline. Eur. J. Pharmacol. 78, 345-351.
21. 3H]desipramine to rat brain: A presynaptic marker for noradrenergic uptake sites. J. Neurochem. 38, 889-895.
22. Rosenspire K. C., Haka M. S., van Dort M. E., Jewett D. M., Gildersleeve D. L., Schwaiger M. and Wieland D. M. (1990) Synthesis and preliminary evaluation of carbon-11-meta-hydroxyephedrine: a false transmitter agent for heart neuronal imaging. J. Nucl. Med. 31, 1328-1334.
23. Schwaiger M., Kalff V., Rosenspire K., Haka M. S., Molina E., Hutchins G. D., Deeb M., Wolfe E. Jr. and Wieland D. M. (1990) Noninvasive evaluation of sympathetic nervous system in human heart by positron emission tomography. Circulation 82, 457-464.
24. Schwaiger M., Hutchins G. D., Kalff V., Rosenspire K., Haka M. S., Mallette S., Deeb G. M., Abrams G. D. and Wieland D. (1991) Evidence for regional catecholamine uptake and storage sites in the transplanted human heart by positron emission tomography. J. Clin. Invest. 87, 1681-1690.
25. Swann A.C., Duman R. and Hewitt L. (1985) Desipramine binding: Relationship to central and sympathetic noradrenergic activity. J. Neurochem. 44, 611-615.
26. 18F]fluorometaraminol. J. Med. Chem. 33, 956-964.
27. 3H]-desipramine in central nerve terminals studied with electron microscope auroradiography and subcellular fractionation. Experientia 35, 1210-1212.